Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases ...Middle East

Medicxi co-led Company's US$70 million Series A less than 2 years ago Third Medicxi portfolio exit to US biopharma in last 12 months LONDON, GENEVA and JERSEY, British Isles, July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its...

Hence then, the article about medicxi asset centric portfolio company versanis bio to be acquired by lilly to improve patient outcomes in cardiometabolic diseases was published today ( Friday 14/07/2023 - 03:09 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases )

Also on site :

• 2000s Heavy Metal Rocker Makes $1.5 Million Move Before 2026 Tour
• Wayfair’s 'Modern' and 'Functional' 3-Drawer Dresser Is on Sale for $48, and It’s 'Perfect' for Small Spaces
• “Bolivia no duerme”: entre la confianza y el nerviosismo, un país entero espera el repechaje al Mundial 2026